Aastrom Biosciences, Inc. Appoints Daniel R. Orlando as Chief Commercial Officer

Published: Sep 05, 2012

ANN ARBOR, Mich., Sept. 5, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced the appointment of Daniel (Dan) R. Orlando as chief commercial officer, a newly created position at Aastrom.

Back to news